Bristol-Myers Squibb Co. (BMY) on Friday said it has halted the Phase 3 Librexia ACS trial of milvexian, conducted in partnership with Johnson & Johnson (JNJ), in patients who recently experienced an acute coronary syndrome (ACS) event.
The decision follows an interim analysis conducted by the Independent Data Monitoring Committee, which found the study was unlikely to meet its primary efficacy endpoint.
The Librexia clinical trial program includes two additional Phase 3 studies—Librexia AF for atrial fibrillation and Librexia STROKE for secondary stroke prevention. The monitoring committee recommended these trials proceed as planned, with topline results expected in 2026.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.